Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and subthreshold micropulse laser in diabetic macular edema
NCT05582577Phase 3Unknown
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Oct 2022
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bevacizumab in diabetic macular edema (DME), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Change from baseline central macular thickness at 2 months. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT05582577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05582577.